Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kinross Gold Corporation (KGC) vs Novartis AG (NVS) Price & Performance

Kinross Gold CorporationTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Kinross Gold Corporation vs Novartis AG — how do they compare? Kinross Gold Corporation trades at $27.46 (market cap $32.29B), while Novartis AG trades at $154.71 (market cap $295.37B). The key difference: Novartis AG is far larger — about 9.1× Kinross Gold Corporation's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.

KGCNVS
Market Cap
$32.29B$295.37B
Sector
Basic MaterialsHealth
52-Week High
$38.06$168.62
52-Week Low
$18.70$119.31
Enterprise Value
$30.37B$336.69B
Dividend Yield
0.59%3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kinross Gold Corporation

Kinross Gold (KGC) trades at $27.70, up 1.09% today, with a bullish technical signal from moving averages but overbought RSI levels. The company demonstrates robust fundamentals, with Q2 2026 EPS beating estimates at $0.71 versus $0.66 expected, and strong cash flow growth, with 2025 operating cash flow at $3.76 billion. Recent news includes a credit rating upgrade to 'BBB' by S&P Global Ratings on August 6, 2026, and ongoing project developments like Lobo-Marte.

The outlook is positive, supported by earnings beats, rising gold prices, and a consensus price target of $37.20, implying 34% upside. Risks include cost pressures and gold price volatility, but institutional buying and a 58.6% analyst buy rating suggest confidence in continued growth.

Novartis AG

Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.

The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kinross Gold Corporation

Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.

Read more on KGC

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS